{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:32:32Z","timestamp":1790645552956,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T00:00:00Z","timestamp":1519948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T00:00:00Z","timestamp":1519948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Excellence Cluster Cardio-Pulmonary System"},{"name":"Universities Giessen and Marburg Lung Center"},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/13\/48\/30453"],"award-info":[{"award-number":["FS\/13\/48\/30453"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010564","name":"German Center for Lung Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010564","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Collaborative Research Center (CRC) 1213"},{"name":"British Heart Foundation Project Grant","award":["PG\/06\/125\/21633"],"award-info":[{"award-number":["PG\/06\/125\/21633"]}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["Sheffield Clinical Research Facility"],"award-info":[{"award-number":["Sheffield Clinical Research Facility"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Aldosterone is a mineralocorticoid hormone critically involved in arterial blood pressure regulation. Although pharmacological aldosterone antagonism reduces mortality and morbidity among patients with severe left-sided heart failure, the contribution of aldosterone to the pathobiology of pulmonary arterial hypertension (PAH) and right ventricular (RV) heart failure is not fully understood.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The effects of Eplerenone (0.1% Inspra\u00ae mixed in chow) on pulmonary vascular and RV remodeling were evaluated in mice with pulmonary hypertension (PH) caused by Sugen5416 injection with concomitant chronic hypoxia (SuHx) and in a second animal model with established RV dysfunction independent from lung remodeling through surgical pulmonary artery banding.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Preventive Eplerenone administration attenuated the development of PH and pathological remodeling of pulmonary arterioles. Therapeutic aldosterone antagonism \u2013 starting when RV dysfunction was established - normalized mineralocorticoid receptor gene expression in the right ventricle without direct effects on either RV structure (Cardiomyocyte hypertrophy, Fibrosis) or function (assessed by non-invasive echocardiography along with intra-cardiac pressure volume measurements), but significantly lowered systemic blood pressure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our data indicate that aldosterone antagonism with Eplerenone attenuates pulmonary vascular rather than RV remodeling in PAH.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-018-0604-x","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T04:06:55Z","timestamp":1519963615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension"],"prefix":"10.1186","volume":"18","author":[{"given":"Mario","family":"Boehm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Braithwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Pickworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changwu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Novoyatleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Kiely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Grimminger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein A.","family":"Ghofrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Weissmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph T.","family":"Schermuly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baktybek","family":"Kojonazarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,2]]},"reference":[{"issue":"8","key":"604_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","volume":"8","author":"RT Schermuly","year":"2011","unstructured":"Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol. 2011;8(8):443\u201355.","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"604_CR2","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1172\/JCI33452","volume":"118","author":"M Rabinovitch","year":"2008","unstructured":"Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2008;118(7):2372\u20139.","journal-title":"J Clin Invest"},{"key":"604_CR3","doi-asserted-by":"crossref","unstructured":"Leopold JA, Maron BA. Molecular mechanisms of pulmonary vascular remodeling in pulmonary arterial hypertension. Int J Mol Sci. 2016;17(5)","DOI":"10.3390\/ijms17050761"},{"issue":"2","key":"604_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0008-6363(97)00049-7","volume":"34","author":"NW Morrell","year":"1997","unstructured":"Morrell NW, Danilov SM, Satyan KB, Morris KG, Stenmark KR. Right ventricular angiotensin converting enzyme activity and expression is increased during hypoxic pulmonary hypertension. Cardiovasc Res. 1997;34(2):393\u2013403.","journal-title":"Cardiovasc Res"},{"issue":"8","key":"604_CR5","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1164\/rccm.201203-0411OC","volume":"186","author":"FS de Man","year":"2012","unstructured":"de Man FS, Tu L, Handoko ML, Rain S, Ruiter G, Francois C, Schalij I, Dorfmuller P, Simonneau G, Fadel E, et al. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186(8):780\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"23","key":"604_CR6","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1161\/CIRCULATIONAHA.114.006980","volume":"131","author":"BA Maron","year":"2015","unstructured":"Maron BA, Leopold JA. Emerging concepts in the molecular basis of pulmonary arterial hypertension: part II: Neurohormonal signaling contributes to the pulmonary vascular and right ventricular Pathophenotype of pulmonary arterial hypertension. Circulation. 2015;131(23):2079\u201391.","journal-title":"Circulation"},{"issue":"3","key":"604_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH715>3.0.CO;2-Q","volume":"192","author":"C Orte","year":"2000","unstructured":"Orte C, Polak JM, Haworth SG, Yacoub MH, Morrell NW. Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol. 2000;192(3):379\u201384.","journal-title":"J Pathol"},{"issue":"3","key":"604_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/eurjhf\/hfs173","volume":"15","author":"BA Maron","year":"2013","unstructured":"Maron BA, Opotowsky AR, Landzberg MJ, Loscalzo J, Waxman AB, Leopold JA. Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. Eur J Heart Fail. 2013;15(3):277\u201383.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"604_CR9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1161\/CIRCULATIONAHA.112.094722","volume":"126","author":"BA Maron","year":"2012","unstructured":"Maron BA, Zhang YY, White K, Chan SY, Handy DE, Mahoney CE, Loscalzo J, Leopold JA. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation. 2012;126(8):963\u201374.","journal-title":"Circulation"},{"issue":"7","key":"604_CR10","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1096\/fj.201500042","volume":"30","author":"R Aghamohammadzadeh","year":"2016","unstructured":"Aghamohammadzadeh R, Zhang YY, Stephens TE, Arons E, Zaman P, Polach KJ, Matar M, Yung LM, Yu PB, Bowman FP, et al. Up-regulation of the mammalian target of rapamycin complex 1 subunit raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension. FASEB J. 2016;30(7):2511\u201327.","journal-title":"FASEB J"},{"issue":"10","key":"604_CR11","doi-asserted-by":"publisher","first-page":"L678","DOI":"10.1152\/ajplung.00300.2012","volume":"304","author":"IR Preston","year":"2013","unstructured":"Preston IR, Sagliani KD, Warburton RR, Hill NS, Fanburg BL, Jaffe IZ. Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2013;304(10):L678\u201388.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"2","key":"604_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nm1545","volume":"13","author":"JA Leopold","year":"2007","unstructured":"Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007;13(2):189\u201397.","journal-title":"Nat Med"},{"issue":"2","key":"604_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1161\/CIRCULATIONAHA.113.007690","volume":"130","author":"BA Maron","year":"2014","unstructured":"Maron BA, Oldham WM, Chan SY, Vargas SO, Arons E, Zhang YY, Loscalzo J, Leopold JA. Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis. Circulation. 2014;130(2):168\u201379.","journal-title":"Circulation"},{"issue":"10","key":"604_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709\u201317.","journal-title":"N Engl J Med"},{"issue":"3","key":"604_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/01.mnh.0000165889.60254.98","volume":"14","author":"NJ Brown","year":"2005","unstructured":"Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens. 2005;14(3):235\u201341.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"604_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijcard.2013.08.102","volume":"169","author":"MA Borgdorff","year":"2013","unstructured":"Borgdorff MA, Bartelds B, Dickinson MG, Steendijk P, Berger RM. A cornerstone of heart failure treatment is not effective in experimental right ventricular failure. Int J Cardiol. 2013;169(3):183\u20139.","journal-title":"Int J Cardiol"},{"key":"604_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/VHRM.S13779","volume":"7","author":"JM Nappi","year":"2011","unstructured":"Nappi JM, Sieg A. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vasc Health Risk Manag. 2011;7:353\u201363.","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"604_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/08998280.2004.11927973","volume":"17","author":"J Craft","year":"2004","unstructured":"Craft J. Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. Proc (Baylor Univ Med Cent). 2004;17(2):217\u201320.","journal-title":"Proc (Baylor Univ Med Cent)"},{"issue":"6","key":"604_CR19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/00005344-200306000-00019","volume":"41","author":"S Keidar","year":"2003","unstructured":"Keidar S, Hayek T, Kaplan M, Pavlotzky E, Hamoud S, Coleman R, Aviram M. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2003;41(6):955\u201363.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"18","key":"604_CR20","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1161\/01.CIR.0000127949.05756.9D","volume":"109","author":"S Keidar","year":"2004","unstructured":"Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004;109(18):2213\u201320.","journal-title":"Circulation"},{"issue":"2","key":"604_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1113\/EP085963","volume":"102","author":"M Boehm","year":"2017","unstructured":"Boehm M, Lawrie A, Wilhelm J, Ghofrani HA, Grimminger F, Weissmann N, Seeger W, Schermuly RT, Kojonazarov B. Maintained right ventricular pressure overload induces ventricular-arterial decoupling in mice. Exp Physiol. 2017;102(2):180\u20139.","journal-title":"Exp Physiol"},{"key":"604_CR22","volume":"2015","author":"W Janssen","year":"2015","unstructured":"Janssen W, Schymura Y, Novoyatleva T, Kojonazarov B, Boehm M, Wietelmann A, Luitel H, Murmann K, Krompiec DR, Tretyn A, et al. 5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure. Biomed Res Int. 2015;2015:438403.","journal-title":"Biomed Res Int"},{"issue":"3","key":"604_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/cvr\/cvw065","volume":"111","author":"L Shi","year":"2016","unstructured":"Shi L, Kojonazarov B, Elgheznawy A, Popp R, Dahal BK, Bohm M, Pullamsetti SS, Ghofrani HA, Godecke A, Jungmann A, et al. miR-223-IGF-IR signalling in hypoxia- and load-induced right-ventricular failure: a novel therapeutic approach. Cardiovasc Res. 2016;111(3):184\u201393.","journal-title":"Cardiovasc Res"},{"issue":"11","key":"604_CR24","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/nm.3695","volume":"20","author":"R Savai","year":"2014","unstructured":"Savai R, Al-Tamari HM, Sedding D, Kojonazarov B, Muecke C, Teske R, Capecchi MR, Weissmann N, Grimminger F, Seeger W, et al. Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. Nat Med. 2014;20(11):1289\u2013300.","journal-title":"Nat Med"},{"key":"604_CR25","doi-asserted-by":"crossref","unstructured":"Budas GR, Boehm M, Kojonazarov B, Viswanathan G, Tian X, Veeroju S, Novoyatleva T, Grimminger F, Hinojosa-Kirschenbaum F, Ghofrani HA, et al. ASK1 inhibition halts disease progression in preclinical models of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2017","DOI":"10.1164\/rccm.201703-0502OC"},{"issue":"11","key":"604_CR26","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1084\/jem.20112716","volume":"209","author":"AG Hameed","year":"2012","unstructured":"Hameed AG, Arnold ND, Chamberlain J, Pickworth JA, Paiva C, Dawson S, Cross S, Long L, Zhao L, Morrell NW, et al. Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. J Exp Med. 2012;209(11):1919\u201335.","journal-title":"J Exp Med"},{"issue":"4","key":"604_CR27","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.ajpath.2011.06.037","volume":"179","author":"A Lawrie","year":"2011","unstructured":"Lawrie A, Hameed AG, Chamberlain J, Arnold N, Kennerley A, Hopkinson K, Pickworth J, Kiely DG, Crossman DC, Francis SE. Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner. Am J Pathol. 2011;179(4):1693\u2013705.","journal-title":"Am J Pathol"},{"issue":"4","key":"604_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S2213-2600(15)00542-1","volume":"4","author":"MM Hoeper","year":"2016","unstructured":"Hoeper MM, McLaughlin VV, Dalaan AM, Satoh T, Galie N. Treatment of pulmonary hypertension. Lancet Respir Med. 2016;4(4):323\u201336.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"604_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ijcard.2008.04.056","volume":"129","author":"J Therrien","year":"2008","unstructured":"Therrien J, Provost Y, Harrison J, Connelly M, Kaemmerer H, Webb GD. Effect of angiotensin receptor blockade on systemic right ventricular function and size: a small, randomized, placebo-controlled study. Int J Cardiol. 2008;129(2):187\u201392.","journal-title":"Int J Cardiol"},{"issue":"3","key":"604_CR30","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1161\/CIRCULATIONAHA.112.135392","volume":"127","author":"T van der Bom","year":"2013","unstructured":"van der Bom T, Winter MM, Bouma BJ, Groenink M, Vliegen HW, Pieper PG, van Dijk AP, Sieswerda GT, Roos-Hesselink JW, Zwinderman AH, et al. Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial. Circulation. 2013;127(3):322\u201330.","journal-title":"Circulation"},{"issue":"14","key":"604_CR31","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"604_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"11","key":"604_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143954","volume":"10","author":"E Montes-Cobos","year":"2015","unstructured":"Montes-Cobos E, Li X, Fischer HJ, Sasse A, Kugler S, Didie M, Toischer K, Fassnacht M, Dressel R, Reichardt HM. Inducible knock-down of the mineralocorticoid receptor in mice disturbs regulation of the renin-angiotensin-aldosterone system and attenuates heart failure induced by pressure overload. PLoS One. 2015;10(11):e0143954.","journal-title":"PLoS One"},{"issue":"4","key":"604_CR34","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.110.163287","volume":"57","author":"A Lother","year":"2011","unstructured":"Lother A, Berger S, Gilsbach R, Rosner S, Ecke A, Barreto F, Bauersachs J, Schutz G, Hein L. Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension. 2011;57(4):746\u201354.","journal-title":"Hypertension"},{"issue":"4","key":"604_CR35","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1161\/01.CIR.0000153800.09920.40","volume":"111","author":"GM Kuster","year":"2005","unstructured":"Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, Sam F. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111(4):420\u20137.","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.1186\/s12890-022-01978-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000}}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-018-0604-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-018-0604-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-018-0604-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T14:05:22Z","timestamp":1658325922000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-018-0604-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["604"],"URL":"https:\/\/doi.org\/10.1186\/s12890-018-0604-x","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12890-022-01978-0","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,2]]},"assertion":[{"value":"3 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12890-022-01978-0","URL":"https:\/\/doi.org\/10.1186\/s12890-022-01978-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments were performed according to the institutional guidelines that comply with national and international regulations (EU directive 2010\/63). The local authorities for animal research approved the study protocol (Regierungspr\u00e4sidium Giessen, Germany, Gi 32\/2013 and The UK Home Office under PPL 40\/3517).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"41"}}